PRDM13

Across TCGA pan-cancer cohorts, PRDM13 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRDM13 data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRDM13 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PRDM13 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and GBM are the cancer types where PRDM13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.785	0.314	.012	25	view →
HNSC	DFS	Median	All	0.930	0.625	.011	16	view →
GBM	DFS	Quartile	All	0.457	0.202	.028	5	view →
LSCC	OS	Median	III,IV	1.000	0.504	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRDM13–PDAC (OS)

Open the PDAC breakdown →